Skip to main content
EJNMMI Physics
Fig. 3 | EJNMMI Physics

Fig. 3

From: Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

Fig. 3

Lesion-based scatter plots of the cumulative tumour-absorbed dose (TAD) against the diameter change of the target lesion (%). A Cumulative TADmax: Diameter change (%) of the target lesion was > –20% (disease control state according to RECIST 1.1 criteria) when the cumulative dose was ≥ 107.4 Gy (vertical red line). B Cumulative TADpeak: Diameter change (%) of the target lesion was > –20% (disease control state according to RECIST criteria) when the cumulative dose was ≥ 93.7 Gy (vertical red line). C Cumulative TAD41: Diameter change (%) of the target lesion was > –20% (disease control state according to RECIST criteria) when the cumulative dose was ≥ 65.4 Gy (vertical red line)

Back to article page